Please login to the form below

Not currently logged in
Email:
Password:

TS23

This page shows the latest TS23 news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo licenses clot-busting antibody

Daiichi Sankyo licenses clot-busting antibody

The drug candidate - called TS23 - is in phase I trials but has shown "exceptional efficacy and safety in multiple disease models", according to Memphis-based Translational Sciences. ... It will pay Translational Sciences unspecified fees, milestones and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...